Webinar Date/Time: Airing 1: Wednesday, January 31, 2024 at 9am EST | 2pm GMT | 3pm CET Airing 2: Wednesday, January 31, 2024 at 1pm EST | 12pm CST | 10am PST
This webinar highlights antibody-drug conjugate (ADC) analysis and separation of multiple-conjugated drug-to-antibody ratio (DAR) variants using hydrophobic interaction chromatography (HIC).
Register Free: https://www.chromatographyonline.com/lcgc_w/antibody-drug
Event Overview:
Antibody-drug conjugates (ADCs) are dual-action cancer biotherapeutics, where monoclonal antibodies carrying tumor-killing payloads specifically bind to cancer cells and accelerate cancer cell death. Characterizing the ratio of tumor-killing payload to cancer-binding antibody (DAR) is a critical quality attribute needed to determine the potential potency of a given ADC candidate. This webinar features hydrophobic interaction chromatography (HIC) as a solution for quantifying DARs in ADC biotherapeutics. An overview of ADC and HIC fundamentals will be presented, targeting analytical method development scientists seeking insights for mobile-phase and stationary-phase selections for separating variable conjugated ADC variants.
Key Learning Objectives:
Who Should Attend:
Speaker:
Corey Meadows
Regional products Specialist
Tosoh Bioscience, LLC
Corey Meadows obtained his Ph.D. in physical chemistry at the University of California, Berkeley in 2014. He served as an analytical development scientist in the renewables and biopharmaceutical industries, focusing on HPLC, LC-MS, and GC-MS techniques for small and large molecule analyses. While working within the biopharmaceutical industry, he focused primarily on antibody and protein therapeutic characterization using high-resolution UPLC-MS methods. As a regional product specialist at Tosoh Bioscience, Corey focuses on application support and product development for analytical columns and multi-angle light scattering (MALS) detectors.
Register Free: https://www.chromatographyonline.com/lcgc_w/antibody-drug